Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 4Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Bites and Stings 1

Interventions

pembrolizumab 1durvalumab 1dostarlimab 1atezolizumab 1Etoposide 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bites and Stings × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡